By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Drug Cos. Using REMS to Delay Generic Competition
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Drug Cos. Using REMS to Delay Generic Competition
BusinessNewsPolicy & LawSpecialties

Drug Cos. Using REMS to Delay Generic Competition

gooznews
gooznews
Share
6 Min Read
SHARE

Five years ago in the wake of the Vioxx scandal, Congress passed tough new distribution rules for companies whose prescription drugs pose a serious risk to patients when misused. Now generic manufacturers are complaining those same rules are being used to thwart competition that could save consumers and taxpayers billions of dollars over the next decade.

Five years ago in the wake of the Vioxx scandal, Congress passed tough new distribution rules for companies whose prescription drugs pose a serious risk to patients when misused. Now generic manufacturers are complaining those same rules are being used to thwart competition that could save consumers and taxpayers billions of dollars over the next decade.

Exhibit one in the generic industry’s brief involves thalidomide, whose use as an anti-nausea medication during pregnancy was banned in the early 1960s because it caused horrific birth defects in a handful of European countries where it had been approved. In the late 1990s, the drug, now marketed as Thalomid by Celgene, made a comeback, first as a medication for leprosy and then, in 2006, for some cancers.

But the FDA required its manufacturer adopt a “risk evaluation and mitigation strategy” (REMS) under the post-Vioxx law. It demanded Celgene maintain strict controls on distribution of the drug and obtain signed waivers from prescribing physicians saying they were aware of the risks, especially to pregnant women.

In 2009, with the first patents on the new uses for Thalomid nearing expiration, Dr. Reddy’s Laboratories, Inc., a New Jersey-based generic manufacturer, asked Celgene for samples so it could prepare a generic formulation. The company refused.

In a citizen’s petition to the FDA, Dr. Reddy’s officials complained that unless the FDA acted, “consumers will be prevented from having timely access to generic versions of an increasing number of important drugs.” The FDA, which has approved over 80 REMS in the past few years, many of them for expensive biologics that will face generic competition for the first time in the coming decade, did nothing.

Efforts to close the loophole have become the subject of a fierce behind-the-scenes lobbying campaign on rival bills that reauthorize industry user fees, which are now before a Congressional conference committee. The bill must pass since user fees now account for over half of the Food and Drug Administration’s drug division budget.

The Senate bill, which passed in a near unanimous vote last month, required that brand-name manufacturers cooperate with potential generic competitors by turning over samples of the more dangerous drugs. But the House version stripped the requirement after the Pharmaceutical Research and Manufacturers of America (PhRMA), the industry trade group, voiced opposition. The bill is now in conference.

“This stuff sounds arcane, but it has enormous potential to cost consumers tens of billions of dollars,” said Ralph Neas, president of the Generic Pharmaceutical Association. “Brand companies are using REMS to prevent generic companies from getting samples for testing.”

The group has lined up support from AARP, pharmacy benefit managers (PBMs), which manage prescription drug benefit plans for major employers, and a wide range of consumer groups. “The average price of generic drugs is $40 a month or 75 percent less than brand name drugs,” said David Certner, a lobbyist for AARP, which claims a membership of 20 million older Americans. “With biologics soon to be eligible for generic competition, it is absolutely critical that they be made affordable.”

According to generic proponents, PhRMA and the Biotechnology Industry Organization have inundated Capitol Hill with lobbyists in recent weeks to keep the Senate provision out of the final bill. The drug industry and other health-related firms rank number one among all industries in lobbying this year, according to the Center for Responsive Politics, having spent $67 million in the first quarter alone, which is 50 percent more than any other industry. The top five lobbying groups for all of health care were PhRMA ($5.3 million), Merck ($4.5 million), Pfizer ($3.5 million), Eli Lilly ($2.9 million) and Novartis ($2.8 million).

PhRMA senior vice president Matthew Bennett, in a prepared statement, did not comment directly on the issue, but did say that “REMS were not created to serve the interests of the generic drug or PBM sectors. When REMS are imposed on companies by the FDA,” he said, “it is within the context of patient safety, and that should continue to be the focus moving forward.”

TAGGED:pharma
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025
AI in Healthcare
AI in Healthcare: Technology is Transforming the Global Landscape
Global Healthcare Policy & Law Technology
October 1, 2025
Choosing the Right Swimwear for Health and Safety
News
September 30, 2025
sports concussions
Concussion In Sports: How Common They Are And What You Need To Know
Infographics
September 28, 2025

You Might also Like

healthcare access recover injury
HealthPolicy & Law

Healthcare Disparities Make it Harder to Recover from Injuries

June 1, 2024
Image
eHealthFinanceSocial MediaTechnology

Removing the Digital Content Barriers

March 8, 2013
BusinesseHealthMedical DevicesMedical InnovationsNews

Top 10 Innovative Companies In Healthcare 2012

October 15, 2012
privacy-policy-510731_1920
eHealthPolicy & Law

“What we need is more regulation . . . .”

July 28, 2016
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?